Total
0
Shares
G Medical Innovations (ASX:GMV) - CEO, Dr Yacov Geva
CEO, Dr Yacov Geva
Source: Small Caps
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • G Medical (GMV) has been granted TGA (Therapeutics Goods Administration) approval for its G Medical Holter Patch (GMP)
  • The GMP streamlines and simplifies patient monitoring by providing real-time and continuous monitoring for up to two weeks
  • It can measure heart rate, blood pressure, body temperature, heart rhythm, body position, and location
  • It’s typically used for those in assisted living residences and hospitals
  • The company is now looking for approval in other countries such as the U.S.
  • G Medical is steady on the market this morning and shares are trading for 9.4 cents each

G Medical (GMV) has been granted TGA (Therapeutics Goods Administration) approval for its G Medical Holter Patch (GMP).

This marks an important milestone for the medical device company as its GMP now complies with all relevant medical and safety requirements for a Class IIa medical device in Australia.

A class IIa medical device is classified as low to medium risk and concern devices that are installed in the body in the short term, between 60 minutes and 30 days.

Examples include catheters, hearing aids, and blood transfusion tubes.

This TGA approval adds onto the already granted European CE Class II approval and G Medical is now seeking the green light for GMP in other countries, such as the U.S.

What is the GMP?

The GMP is a modular, easy-to-use clinical-grade solution used for monitoring patients throughout the healthcare lifecycle.

It’s typically used for those in assisted living residences and hospitals as it streamlines and simplifies patient monitoring by providing real-time and continuous monitoring for up to two weeks.

The GMP device
Sourced: G Medical

It can measure heart rate, blood pressure, body temperature, heart rhythm, body position, and location.

Patients can also mark a cardiac event, such as a heart attack, which will notify their doctor and relevant medical staff.

“TGA certification is a significant milestone for G Medical and demonstrates how the company’s suite of medical devices and telehealth technologies are relevant to the current environment,” CEO Dr Yacov Geva commented.

“The company continues to pursue regulatory approvals for both the GMP and the Prizma device in its target markets and looks forward to updating shareholders as they are granted,” he said.

G Medical is steady on the market this morning and shares are trading for 9.4 cents each at 10:21 am AEST.

GMV by the numbers
More From The Market Herald
Race Oncology (ASX:RAC) - MD and CEO Phillip Lynch

" Race Oncology (ASX:RAC) secures sixth US patent for Zantrene

Race Oncology (RAC) has locked in its sixth US patent for its cancer drug, Zantrene.
Heramed (ASX:HMD) - CEO and Co Founder, David Groberman

" HeraMED (ASX:HMD) raises $2.39m via convertible note placement

HeraMED (HMD) has raised roughly $2.39 million through a convertible note placement.
NeuroScientific Biopharmaceuticals (ASX:NSB) - MD and CEO, Matthew Liddelow

" NeuroScientific Biopharmaceuticals (ASX:NSB) completes safety pharmacology studies

NeuroScientific Biopharmaceuticals (NSB) has seen no adverse events during its non-clinical studies of EmtinB.
PharmAust (ASX:PAA) - Chief Scientific Officer, Dr Richard Mollard

" PharmAust (ASX:PAA) identifies optimal MPL dose for canine cancer

Clinical-stage biotech company PharmAust (PAA) has identified the optimum monepantel (MPL) drug plasma range for dogs with B-cell lymphoma.